Corcept Fair Value
HT
The fair market value of HTD.F stock is 29.51 EUR. Relative to the market price of 53.76 EUR Corcept is overvalued by 46.2%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Corcept Valuation
Current HTD.F share ticker price is 53.76 EUR.
The fair value level of 29.51 EUR can be considered as an effective entry point for long-term investors to start investing in HTD.F stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Current price is 45% higher its fair value
Current price is 58% higher its minimum value
Current price is 29% higher its maximum value
Market price:
HTD.F stock is greatly overvalued
It means the current price may concern as a High Risk Entry Point
Corcept Therapeutics Inc Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
29.62
2
Median P/E over 5 years
22.95
3
Minimum P/E over 5 years
17.64
4
Earning per share (last 12 months)
1.37 USD
Maximum value
1
x
4
=
38.09 EUR
Fair value
2
x
4
=
29.51 EUR
Minimum value
3
x
4
=
22.68 EUR
Corcept Therapeutics Inc price metrics
30.24
Annual return (geometric mean)
53.32
Risk (standard deviation) of returns
β
1.75
Beta (volatility compared to market)